Communication Training for Doctors Treating Large B-Cell Lymphoma
Tests a new training to help doctors talk with adults about lymphoma and care planning.
Plain-language title generated from the registry record
Registry title: Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Key facts
- Where
- New York, United StatesSee the 2 sites
Where in United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesTaking people
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)New York, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT05940272
- Record updated
- 13 October 2026
- Original description
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.Read full original descriptionShow less
Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Inclusion: Providers; Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma); Patients; Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis); Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma; Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT); Self-identify as Black and/or White; Per medical record, 18 years of age or older; Per self-report, fluent in English**; Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:; How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused); What is your preferred language for healthcare? (must respond English).
Exclusion: Per medical record or self-report, receiving hospice care at the time of enrollment; Per self-report, planning to leave the cancer center in the next 12 months; Patients; Providers; Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11; Per research staff judgment and/or self-report, too ill or weak to complete study procedures.